Pharma

Despite the plethora of drugs currently available for patients with psoriatic arthritis (PsA), several key unmet needs remain, according to GlobalData, a leading data and analytics company.The company’s report: ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’ reveals...

The bladder cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 18.5%, according to GlobalData, a leading data and...

In the event of a free trade agreement with the EU, the UK will continue to be bound by current EU laws, thereby adhering to the new Medical Device Regulation (MDR). This will significantly change the landscape of the medical device industry, says GlobalData, a leading data...

Following the recent news that Roche’s Phase III influenza drug Xofluza met its primary endpoint for influenza prevention, Philipp Rosenbaum, Pharma Analyst at GlobalData, a leading...

Pills on a white background

Multiple big pharma companies are developing new anti-obesity drugs, including Novo Nordisk, Sanofi, and AstraZeneca and six drugs are expected to launch by 2026, according...

pills medicine healthcare

Takeda’s possible $65B takeover of Shire could be the largest deal value in pharma this year, says GlobalData a leading data and analytics company. This...

NASH webinar- Understand the NASH Market Landscape

Affecting more than 60 million people worldwide, and with no approved therapies, nonalcoholic steatohepatitis (NASH) presents a wealth of opportunities for drug developers. Join GlobalData's...

Slow growth in pharmaceutical sales over recent years has spurred considerable interest and investment into emerging global markets: Brazil, Russia, India, China and South Korea...